Evaluating Pembrolizumab, Bevacizumab, and Oral Metronomic Cyclophosphamide in Heavily Pretreated Platinum-Resistant Ovarian Cancer: Real-World Outcomes and Clinical Implications
Posted innews OB/GYN & Women's Health Oncology

Evaluating Pembrolizumab, Bevacizumab, and Oral Metronomic Cyclophosphamide in Heavily Pretreated Platinum-Resistant Ovarian Cancer: Real-World Outcomes and Clinical Implications

This study assesses the efficacy and safety of pembrolizumab combined with bevacizumab and oral metronomic cyclophosphamide in heavily pretreated platinum-resistant ovarian cancer patients, showing modest disease control with manageable toxicity in a real-world setting.
Sacituzumab Govitecan plus Pembrolizumab Extends Progression-Free Survival in First-Line PD-L1-Positive Advanced TNBC
Posted innews Oncology

Sacituzumab Govitecan plus Pembrolizumab Extends Progression-Free Survival in First-Line PD-L1-Positive Advanced TNBC

The phase 3 ASCENT-04/KEYNOTE-D19 trial demonstrates that sacituzumab govitecan plus pembrolizumab significantly improves progression-free survival and duration of response compared to standard chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1-positive advanced triple-negative breast cancer.